ADD TO BW2488, CA-TITAN-PHARMACEUTICALS.

Business Editors

--(BUSINESS WIRE)

ADD to BW2488 (CA-TITAN-PHARMACEUTICALS) Titan Pharmaceuticals, Inc. Announces Third Quarter 2000 Financial Results, after last graph xxx financial tables.

                      TITAN PHARMACEUTICALS, INC.
            CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                (in thousands, except per share amount)

                            Three Months Ended       Nine Months Ended
                               September 30,           September 30,
                            ------------------       -----------------
                            2000          1999       2000         1999
                            ----          ----       ----         ----
                                            (unaudited)
Contract, license and
 grant revenue              $695           $52     $1,311          $99

Operating expenses:
 Research and development  4,576         1,748     11,887        6,558
 Acquired in-process
  research and development 4,969             -      4,969          136
 General and
  administrative           1,247           838      2,808        2,154
                           -----         -----      -----        -----
  Total operating
   expenses               10,792         2,586     19,664        8,848
                          ------         -----     ------        -----
Loss from operations     (10,097)       (2,534)   (18,353)      (8,749)
 Interest and other
  income, net              1,386            89      3,571          378
                          ------         -----     ------        -----
Net loss                 $(8,711)      $(2,445)   $14,782      $(8,371)
                          ======         =====     ======        =====

Basic and diluted net
 loss per share           $(0.34)       $(0.16)    $(0.59)      $(0.55)
                          ======         =====     ======        =====

Weighted average shares
 used in computing basic
  and diluted net loss
   per share              25,872        15,454     25,171       15,180
                          ======        ======     ======       ======

                CONDENSED CONSOLIDATED BALANCE SHEETS

                                        September 30,     December 31,
                                           2000              1999
                                        -------------     ------------
                                        (unaudited)         (Note A)

Assets
 Cash, cash equivalents, and
  short-term investments                      $79,797          $46,454
 Grants receivable, prepaid expenses
  and other current assets                        286              477
                                              -------           ------
  Total current assets                         80,083           46,931
 Furniture and equipment, net                     527              415
 Other assets                                      16               16
                                              -------           ------
                                              $80,626          $47,362
                                              =======           ======

Liabilities and Stockholders' Equity
 Current liabilities                           $2,975           $1,819
 Minority interest - Series B preferred
  stock of Ingenex, Inc.                        1,241            1,241
 Stockholders' Equity                          76,410           44,302
                                              -------           ------
                                              $80,626          $47,362
                                              =======           ======

      Note A: The balance sheet has been derived from the audited
financial statements at that date but does not include all of the
information and footnotes required by generally accepted accounting
principles for complete financial statements presentation.